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The Editorial on the Research Topic
Searching for Immune Tolerance Manipulating New Molecules and Exploiting New Concepts 
on Lymphocyte Biology
This research topic was inspired in those still non-curable inflammatory conditions, such as autoim-
mune diseases and transplant rejection, based on the fact that immunologists worldwide are still 
searching for strategies to restore long-term immune tolerance. Thus, we gathered several research-
ers whom actively base their investigation lines in novel molecules and immune cell populations that 
can be exploited to design new strategies for the establishment or recovery of tolerance.
In the context of autoimmunity, intriguing is the role of interferon (IFN)-γ in the pathogenesis 
of multiple sclerosis (MS) and its animal model, the experimental autoimmune encephalomyelitis, 
which is reviewed in two articles contained in this edition (Ottum et al.; Arellano et al.). They focus 
on new evidence that help to explain the seemingly opposing effects of this cytokine over different 
central nervous system cells and on different stages of the disease, giving some important clues that 
can help to guide the potential therapeutic use of IFN-γ in MS patients. Other cytokine that recently 
has been focus of interest is IL-33, a molecule first described as an alarmin, but Gajardo-Carrasco 
et al. detail the plethora of now recognized functions in which IL-33 is involved, with special atten-
tion in T cell biology, adaptive immunity, tolerance, and immunological disorders.
Continuing with an update on molecules with pivotal immune function, Le Mercier et al. and 
Guo and Wang deliver us a solid snap shot on receptors and ligands with stimulatory and inhibitory 
immune activity, revising both classic and newest members, their contribution to disease and how 
they have been currently targeted to utilize them for therapeutic purposes. Special attention received 
the new Ig family member VISTA, which is presented as an interesting modulator of the immune 
response and with high potential for its exploitation in the clinic.
Similarly, the article by Iruretagoyena et al. addresses the immune regulatory aspects of vitamin 
D and its importance in controlling the development of autoimmune diseases. This review has a 
particular emphasis on the participation of this vitamin in the physiopathology of systemic lupus 
erythematosus (SLE) and gives an update on the latest data about vitamin D supplementation in 
SLE patients.
Regarding the use of immune cells with therapeutic purposes, this research topic contains five 
reviews that put the spotlight over the use of dendritic cells (DCs) and regulatory T cells (Tregs) as 
tools to treat immune-related conditions (including autoimmunity and transplant rejection). The 
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article by Schinnerling et  al. summarizes the recent advances 
in the description of intracellular pathways and transcriptional 
regulators that command the monocyte-derived tolerogenic 
human DCs differentiation program and propose candidate 
molecules that could be regarded as key in their tolerogenic func-
tions. On the other hand, Maggi et al. examine one of the putative 
mechanisms of action of tolerogenic DCs; this is the induction 
of hyporesponsive or anergic CD4+ T cells. The authors review 
recent findings in the impact of CD4+ T cells anergy induction 
in animal models of autoimmune diseases development and 
progression, and discuss on the potential benefits of exploiting 
this mechanism for therapeutic purposes in humans. Similarly, 
Osorio et  al. present a complete revision on DCs nature, from 
their origin, lineages, differentiation process, subtypes, and physi-
ological role, linking these observations with diseases and men-
tioning current technological approaches to use them as a source 
for cellular therapy. On the other hand, Safinia et al. and Gregori 
et al. targeted human Tregs, describing extensively all their phe-
notypic characteristics, the different subpopulations identified 
to date based on certain surface markers and their mechanisms 
to drive immune suppression, and compiling simultaneously all 
the results from finished and ongoing clinical trials. In addition, 
both works discuss different aspects of human Tregs clinical grade 
manufacture and the variables that need to be improved to perfect 
the protocol, such as viability, antigen-specificity, cell expansion 
efficiency, and phenotypic/functional stability.
In parallel, the original article by Ruiz et al. proposes a modi-
fied protocol to favor mixed chimerism and further transplant 
acceptance in a preclinical model. Their novelty bases in the use 
of antigen-specific Tregs generated in  vitro in the presence of 
IL-2, TGF-β, and retinoic acid (RA), in conjunction with previ-
ously established procedures as non-myeloablative irradiation 
and administration of immunosuppressant drugs. This group 
observed that the transfer of RA-Tregs facilitates donor-cells 
engraftment and allows for the acceptance of skin allografts, 
proposing the inclusion of Tregs as co-therapeutic tool. Another 
article reports how Soto et al. pinpoint at another cell population, 
frequently overlooked when it comes to tolerance mechanisms: 
B cells. Using systemic sclerosis (SSc) as a paradigmatic autoim-
mune disease with cellular and humoral components, the authors 
describe alterations in the expression levels of activator and 
inhibitor receptors on B cells from SSc patients that could con-
tribute with the hyperactivated phenotype of these cells. They also 
demonstrate that IL-10-producing B cells and IL-10 secretion by 
stimulated B cells are reduced in SSc patients, which can imply 
that these patients have an impaired anti-inflammatory function 
on regulatory B cells, a subset specifically dedicated to promote 
tolerance to innocuous antigens. The restoration of the capacity of 
these cells to express adequate levels of protolerogenic molecules 
and regain their regulatory capability through novel or current 
B cell-targeted therapies could be a promising therapy for SSc or 
related autoimmune diseases.
Finally, the review by Parigi et  al. brings us to a different 
face of immune tolerance, the one that keep us from mounting 
exacerbated immune responses against food antigens and com-
mensal microbiota. Disruptions of the tolerogenic mechanisms 
displayed by a normal intestinal immune system can lead to 
severe conditions, such as food allergy or inflammatory bowel 
diseases. This review deals with the way how diet, breast milk, and 
solid food shape the immune system of newborns and defines the 
homeostasis in the intestinal microenvironment, thus conferring 
risk or protection for the future development of immune medi-
ated diseases.
Overall, we achieved putting together a nice compilation on 
the current molecules and cell populations that are being aggres-
sively targeted to restore immune tolerance in diseased patients. 
While many efforts are put in translational immunology, basic 
science immunologists continue working to satisfy these goals.
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